ACST Stock – (NASDAQ: ACST) is giving an update on the usage
As necessary pursuant to the policies of the TSX Venture Exchange, Acasti Pharma Inc. (“Acasti or the “Company”) ACST Stock (NASDAQ: ACST – TSX-V: ACST) is actually giving an update on the usage of the “at the market” equity of its providing plan.
As previously disclosed, Acasti entered into an amended as well as restated ATM sales agreement on June 29, 2020 (the “Sales Agreement”) with B. Riley FBR Inc., Oppenheimer & Co. Inc. along with H.C. Co. and Wainwright, LLC (collectively, the “Agents”), to put into practice a “at the market” equity offering program under which Acasti may well issue as well as promote from time to time its common shares having an aggregate offering price of up to $75 million in the Agents (the “ATM Program”).
ACST Stock – Pursuant to the ATM Program, as required pursuant to the policies of the TSX Venture Exchange (“TSXV”), since the last distributions found on January 27, 2021, Acasti given an aggregate of 20,159,229 typical shares (the “ATM Shares”) over the NASDAQ Stock Market for aggregate gross proceeds to the Company of US$21.7 zillion. The ATM Shares had been sold at prevailing market rates averaging US$1.0747 a share. No securities had been sold in the facilities of the TSXV or maybe, to the understanding of the Company, in Canada. The ATM Shares were offered pursuant to a U.S. registration statement on Form S-3 (No. 333 239538) as made effective on July seven, 2020, as well as the Sales Agreement. Pursuant to the Sales Agreement, a money commission of 3.0 % on the aggregate yucky proceeds raised was paid to the Agents in connection with the services of theirs. As a direct result of the recent ATM sales, Acasti has a total of 200,119,659 common shares issued and great as of March 5, 2021.
The extra capital raised has strengthened Acasti’s balance sheet and will supply the Company with more flexibility in its ongoing review process to check out and evaluate strategic options.
About Acasti – ACST Stock
Acasti is a biopharmaceutical innovator that has historically concentrated on the research, development and commercialization of prescribed drugs using OM3 greasy acids delivered both as totally free fatty acids as well as bound-to-phospholipid esters, produced from krill oil. OM3 fatty acids have extensive clinical proof of efficacy and safety for lowering triglycerides in clients with HTG. CaPre, or hypertriglyceridemia, an OM3 phospholipid therapeutic, was being created for clients with serious HTG.
Forward Looking Statements – ACST Stock
Statements of this press release that are not statements of historical or current truth constitute “forward-looking information” to the meaning of Canadian securities laws and “forward looking statements” to the meaning of U.S. federal securities laws (collectively, “forward-looking statements”). Such forward-looking statements include known and unknown risks, uncertainties, and other unknown elements that might cause the particular outcomes of Acasti to be materially different from historical results and as a result of any later outcomes expressed or implied by such forward-looking statements. In addition to statements which explicitly describe these types of risks as well as uncertainties, readers are actually urged to look at statements labeled with the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” “potential,” “should,” “may,” “will,” “plans,” “continue”, “targeted” or some other similar expressions to be uncertain and forward-looking. People are cautioned not to place undue reliance on these forward looking statements, which speak just as of the day of this press release. Forward-looking assertions in this press release include, but are not restricted to, statements or info concerning Acasti’s strategy, succeeding operations as well as the review of its of strategic alternatives.
The forward looking statements contained in this specific press release are expressly qualified in their entirety by this alerting statement, the “Special Note Regarding Forward-Looking Statements” section contained in Acasti’s latest annual report on Form 10-K and quarterly report on Form 10-Q, which are available on EDGAR at www.sec.gov/edgar.shtml, on SEDAR at www.sedar.com as well as on the investor section of Acasti’s site at www.acastipharma.com. Most forward looking assertions in this press release are made as of the day of this press release.
ACST Stock – Acasti does not undertake to upgrade some such forward looking statements whether as a direct result of info which is brand new, future events or otherwise, except as needed by law. The forward looking claims contained herein are also subject generally to assumptions and risks and uncertainties that are discussed from time to time in Acasti’s public securities filings with the Securities as well as exchange Commission and The Canadian securities commissions, including Acasti’s newest annual report on Form 10-K and quarterly report on Form 10 Q under the caption “Risk Factors“.
ACST Stock – (NASDAQ: ACST) is actually giving an update on the usage